Every material Form 8-K OPKO HEALTH, INC. has filed with the SEC since October 02, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
OPKO Health reported third-quarter 2026 revenue from continuing operations of $65.4 million, up 16% from $56.4 million a year earlier, and a narrower operating loss of $31.4 million. The net loss from continuing operations per share widened to $0.05 from $0.04, and the company withdrew its services revenue and total costs guidance because of the pending sale of its BioReference diagnostic operations to Labcorp.
Q3 2026 revenue from continuing operations rose 16% to $65.4 million; operating loss narrowed to $31.4 million from $33.6 million.
Net loss from continuing operations was $35.5 million, or $0.05 per share, versus $33.0 million, or $0.04 per share, a year earlier.
Agreement with Labcorp provides $722 million in cash at closing plus up to $150 million in additional consideration over up to ten years; closing requires regulatory approvals.
Services revenue guidance withdrawn; company issued Q4 2026 product revenue guidance of $41.0 million to $46.0 million and full-year total revenue guidance of $268.0 million to $278.0 million.
OPKO Health and its subsidiary BioReference Health agreed on October 14, 2026, to sell certain assets of BioReference's clinical and anatomic pathology testing business to Laboratory Corporation of America Holdings. The buyer would pay $722 million in cash at closing, plus up to $150 million more over up to ten years based on sales of the 4Kscore prostate cancer test. Closing depends on customary conditions, including HSR antitrust clearance, and is not subject to a financing condition.
Cash purchase price of $722 million at closing, subject to adjustments based on Business revenues at closing
Up to $150 million in additional cash over up to ten years, based on revenue from sales of the 4Kscore test by the buyer
Closing requires HSR antitrust clearance; either party may terminate if the deal has not closed by April 14, 2027, which may be extended by mutual agreement
Buyer would pay OPKO a termination fee of $28,880,000 if the deal ends due to failure to obtain HSR clearance or other required approvals
OPKO Health determined on October 1, 2026 that its 3.75% Convertible Senior Notes due 2029, with about $121 million outstanding, are convertible by holders through December 31, 2026, because the stock traded above the trigger price for enough days in the quarter ended September 30, 2026. The company has elected to settle conversions in common stock, which could add shares for existing holders.
Notes outstanding: about $121 million; conversion right triggered by closing price above $1.495, or 130% of the $1.15 conversion price, for at least 20 of 30 consecutive trading days
Notes convertible through December 31, 2026, and may be convertible after that if Indenture conditions are met in future measurement periods
Holders converting receive 869.5652 common shares per $1,000 principal, plus any additional shares under the Indenture's early conversion provisions
U.S. Bank Trust Company, National Association is trustee and conversion agent
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every OPKO HEALTH, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →